PMC:7417114 / 703-855 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7417114","sourcedb":"PMC","sourceid":"7417114","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7417114","text":"g in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency","tracks":[{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":73,"end":83},"obj":"Chemical"},{"id":"T4","span":{"begin":102,"end":111},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"subj":"T3","pred":"source","obj":"LitCovid-PD-CHEBI"},{"subj":"T4","pred":"source","obj":"LitCovid-PD-CHEBI"}]},{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T3","span":{"begin":66,"end":83},"obj":"http://purl.obolibrary.org/obo/GO_0033673"}],"attributes":[{"subj":"T3","pred":"source","obj":"LitCovid-PD-GO-BP"}]},{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T12","span":{"begin":73,"end":83},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T1117","span":{"begin":73,"end":83},"obj":"CHEBI:35222;CHEBI:35222"}],"attributes":[{"subj":"T12","pred":"source","obj":"LitCovid-PMC-OGER-BB"},{"subj":"T1117","pred":"source","obj":"LitCovid-PMC-OGER-BB"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-PD-CHEBI","color":"#a693ec","default":true},{"id":"LitCovid-PD-GO-BP","color":"#99ec93"},{"id":"LitCovid-PMC-OGER-BB","color":"#ec93b3"}]}]}}